MHY 553 is a PPARα agonist with oral availability that alleviates hepatic steatosis by increasing fatty acid oxidation and reducing inflammation during aging. MHY 553 inhibits triglyceride accumulation induced by liver X receptor agonists in HepG2 cells. MHY 553 significantly inhibits inflammatory mRNA expression in aged rats.

Physicochemical Properties

Molecular Formula	C13H9NO2S
Molecular Weight	243.28
CAS #	6265-56-1
SMILES	OC1C=C(O)C=CC=1C1SC2C=CC=CC=2N=1
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

References

[1]. Novel PPARα agonist MHY553 alleviates hepatic steatosis by increasing fatty acid oxidation and decreasing inflammation during aging. Oncotarget. 2017 May 8;8(28):46273–46285.

Solubility Data

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	4.1105 mL	20.5524 mL	41.1049 mL
	5 mM	0.8221 mL	4.1105 mL	8.2210 mL
	10 mM	0.4110 mL	2.0552 mL	4.1105 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.